These observations, together with the discovery that PK2 can modulate intestinal ion transport, raises the possibility that PK2 inhibitors may have some clinical utility in gastrointestinal disorders, such as irritable bowel syndrome and inflammatory bowel disease [86]. The gene discussed is PROK2; the disease is irritable bowel syndrome.